Fig. 6.

Pembrolizumab alters T cell function, enhances olaparib efficacy, and induces T cell-dependent spheroid death. (a) Cytokine secretion was determined from supernatants collected for both patient samples following VC or pembrolizumab treatment for 48 h. Supernatant was collected from three independent experiments. Depicted is the fold change in cytokine concentrations as determined by normalizing pembrolizumab treatment to VC. (b) 3D spheroids were treated with media (No Tx), VC, olaparib, pembrolizumab, or both olaparib and pembrolizumab (Combo) for 48 h. (c) Representative images of 3D spheroids following 48 h of treatment. Scale bars = 650 μm. (d) Pre 3D bulk T cells were separated and incubated with pembrolizumab. Pre 3D bulk cells were then either cultured with or without treated T cells, and after 48 h, spheroid viability was determined. Spheroid viability for all experiments was determined using CellTiter-Glo® Glo. Unpaired one-way ANOVA with multiple comparison was conducted on the mean of three independent experiments. Error bar = SD. Not significant = n.s., *p < 0.05, **p < 0.01